GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
You may also be interested in...
Glaxo Consumer Finds Growth Groove Via Innovation, Acquisitions, Expansion
GlaxoSmithKline's consumer health care business appears back on track with 8 percent growth in the firm's latest earnings period, a year after it reported flat consumer sales hurt by the disappointing U.S. performance of weight-loss drug alli
GSK Upbeat On Alli In EU As Global Consumer Sales Show Healthy Gains
Alli is off to the races in Europe, where it is generating high sales since launching in April, GlaxoSmithKline says
GSK eyes life after a patent cliff
GlaxoSmithKline is shifting "from being a blockbuster-dependent" company that relies on a single patented drug for a bulk of its revenue to a "blockbuster-ready" firm with a well-diversified portfolio that provides protection if the next big drug comes too late to offset generic competition for the current top-seller, CEO Andrew Witty says. At Cowen & Co.'s Health Care Conference March 17 in Boston, Witty said GSK is seeking diversity rather than the next blockbuster drug to "diminish the possibility of simply going back to another patent cliff," like the one it fell off last year when it lost exclusivity for several prescription drugs. GSK will invest in multiple small prescription drugs and seeks bolt-on acquisitions of vaccines and brands in "the consumer emerging market" to reduce the impact of any one patent expiry, Witty said (1"The Tan Sheet" Feb. 9, 2009, p. 9)